FierceBiotech· @FierceBiotech · X·· 2 小时前精选AI 评分62
AI 导读
Endeavor BioMedicines公布其Hedgehog抑制剂2b期读出结果，显示该药可能成为首个在减少肺纤维化的同时提升总肺容量的药物。该结果被视为对特发性肺纤维化（IPF）现有厂商及大型药企的潜在威胁。
推荐理由
该2b期读出显示Hedgehog抑制剂或能同时减少肺纤维化并提升总肺容量，读者可据此观察IPF治疗格局的潜在变化。
正文
Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing total lung capacity. https://www.fiercebiotech.com/biotech/endeavors-threat-ipf-incumbents-increases-after-phase-2-win-hedgehog-inhibitor
来源：FierceBiotech · x.com